-
A Phase Ib/III Open-label Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced Unresectable or Metastatic Breast Cancer (CAPItello-292)
This is a Phase Ib/III, multicentre study of capivasertib plus CDK4/6i (palbociclib, ribociclib or abemaciclib) and fulvestrant, for the treatment of participants with ...Phase
Interventional
-
A prospective multicenter open-label randomized actively controlled parallel-group Phase 3 clinical trial to evaluate efficacy safety and tolerability of IMA203 versus investigator s choice of treatment in patients with previously treated unresectable or metastatic cutaneous melanoma (ACTengine IMA203-301)
This study is testing a new treatment, IMA203, for patients with advanced skin cancer (cutaneous melanoma) who have already received treatment before. It will compare ...
Phase
Interventional
-
Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) For Intact Brain Metastases
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has ...Phase
Interventional
-
A Phase 3 Randomized Multicenter Double-Blind Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)
The purpose of this research study is to see if an investigational drug, acoramidis (AG10), is safe and effective in preventing or delaying symptoms of ...Phase
Interventional
-
A Phase 3 Randomized Double-blind Placebo-controlled Study of ARD-101 for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome (PWS)
This research study is being done to see if a new drug called ARD-101 can help treat people with hyperphagia due to PWS.Phase
Interventional
-
A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy
This is a randomized, open-label, active-controlled, parallel-group, multicenter, interventional, Phase 3 study of amivantamab and FOLFIRI compared with cetuximab or bevacizumab (investigator’s choice) and ...Phase
Interventional
-
A Phase 3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sj gren s Syndrome With Moderate-to-Severe Symptom State
The Oasiz-303 Study is evaluating the safety and effectiveness of an investigational medicine in people living with Sjögren’s. This investigational medicine works differently from ...Phase
Interventional
-
A Phase 2b / 3 Multicenter Randomized Double-blind Placebo-controlled Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects with End Stage Kidney Disease Undergoing Dialysis
The purpose of this research study is to see if CSL300 (Clazakizumab) is effective and safe in patients on maintenance dialysis at reducing the risk ...Phase
Interventional
-
An Open-label Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician s Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer
This clinical study will evaluate MK-2870 either alone or in combination with pembrolizumab versus TPC in participants with HR+/HER2- (both HER2-zero and HER2-low) unresectable ...Phase
Interventional
-
EASi-HF A Phase III double-blind randomised parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) =40%
The purpose of this clinical research trial is to look at the effectiveness, safety, and tolerance of combining the investigational trial drug called BI 690517 ...Phase
Interventional
